3.22% 0.6587

Arrowhead Pharmaceuticals Inc (ARWR)

Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스

Arrowhead Pharmaceuticals Inc (ARWR)

Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 12-Month Low at $20.04 - MarketBeat

(ARWR) Trading Signals - Stock Traders Daily

Short Interest in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Declines By 17.2% - MarketBeat

TD Asset Management Inc Increases Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 7.6% - MarketBeat

Arrowhead Pharmaceuticals’ Plozasiran Receives Breakthrough Therapy Designation from the FDA - European Pharmaceutical Manufacturer

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low at $20.63 - MarketBeat

FDA grants breakthrough therapy status to Arrowhead’s plozasiran - Pharmaceutical Technology

Arrowhead Pharmaceuticals Becomes Oversold (ARWR) - Nasdaq

ARWR: PALISADE Phase 3 Results Published in NEJM… - Zacks Small Cap Research

ARWR: PALISADE Phase 3 Results Published in NEJM - Research Tree

ARWR: PALISADE Phase 3 Results Published in NEJM… - Yahoo Finance

Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran - Morningstar

Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran - MarketWatch

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - The Bakersfield Californian

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat

Interesting ARWR Put And Call Options For October 18th - Nasdaq

FY2024 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:ARWR) - MarketBeat

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $44.25 - MarketBeat

Principal Financial Group Inc. Sells 59,354 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable - Simply Wall St

Brokers Set Expectations for Arrowhead Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ARWR) - MarketBeat

FY2025 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Raised by Leerink Partnrs (NASDAQ:ARWR) - MarketBeat

Bank of New York Mellon Corp Has $28.20 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - MSN

Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reaffirmed at HC Wainwright - Defense World

Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright - MarketBeat

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - Yahoo Finance

Arrowhead to file NDA after pivotal rare disease trial meets all endpoints - Yahoo Finance

Arrowhead to file NDA after pivotal rare disease trial meets all endpoints - Clinical Trials Arena

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran - MarketWatch

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire

When the Price of (ARWR) Talks, People Listen - Stock Traders Daily

Arrowhead Teeing Up Drug Trials - Los Angeles Business Journal

Arrowhead Pharmaceuticals’ Financing Agreement with Sixth Street - Global Legal Chronicle

Retirement Systems of Alabama Sells 195,492 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

EFG Asset Management North America Corp. Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

ARWR: Two Obesity Assets to Enter the Clinic in 2025… - Yahoo Finance

Arrowhead to present phase 3 data at ESC Congress - Investing.com India

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 6% - MarketBeat

ARWRArrowhead Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Arrowhead to present phase 3 data at ESC Congress By Investing.com - Investing.com Australia

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Familial Chylomicronemia Syndrome Market and Epidemiology - openPR

Arrowhead Pharmaceuticals (STU:HDP1) Enterprise Value : €2,283.57 Mil (As of Aug. 19, 2024) - GuruFocus.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Up 10.8% in July - MarketBeat

Arrowhead takes aim at obesity - BioWorld Online

Arrowhead announces push into obesity space with two gene therapies - Pharmaceutical Technology

Arrowhead announces push into obesity space with two gene therapies - Clinical Trials Arena

FY2024 Earnings Estimate for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Issued By B. Riley - Defense World

FY2024 Earnings Estimate for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Issued By B. Riley - MarketBeat

Arrowhead advances RNAi candidates for obesity treatment By Investing.com - Investing.com Australia

Arrowhead advances RNAi candidates for obesity treatment - Investing.com India

Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases - Morningstar

Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases - MarketWatch

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies - Business Wire

FY2024 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:ARWR) - MarketBeat

FY2024 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:ARWR) - Defense World

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies - StockTitan

ARWR과 유사한 종목